» Articles » PMID: 39282318

Antibiotic Killing of Drug-induced Bacteriostatic Cells

Overview
Journal bioRxiv
Date 2024 Sep 16
PMID 39282318
Authors
Affiliations
Soon will be listed here.
Abstract

Synopsis:

Background: There is a long-standing belief that bacteriostatic drugs are inherently antagonistic to the action of bactericidal antibiotics. This belief is primarily due to the fact that the action of most bactericidal antibiotics requires the target bacteria to be growing. Since bacteriostatic drugs stop the growth of treated bacteria, these drugs would necessarily work against one another. We have recently shown that bacteria treated with high concentrations of bacteriostatic drugs retain some metabolic activity, dividing on average once per day.

Objectives: We seek to determine if this low level of growth is sufficient to allow for bactericidal antibiotics of different classes to still kill after bacteria are treated with bacteriostatic drugs.

Methods: We first treated and with two different bacteriostatic drugs, followed by one of three bactericidal drugs of three different classes. The density of these bacteria was tracked over six days to determine the amount of killing that occurred.

Results: Our results question this long-standing belief by demonstrating conditions where sequential treatment with a bacteriostatic then bactericidal antibiotic is as or more effective than treatment with a bactericidal drug alone.

Conclusions: These results raise the need to investigate the pharmacodynamics of the joint action of bacteriostatic and bactericidal antibiotics and .

References
1.
Morales-Duran N, Leon-Buitimea A, Morones-Ramirez J . Unraveling resistance mechanisms in combination therapy: A comprehensive review of recent advances and future directions. Heliyon. 2024; 10(6):e27984. PMC: 10950705. DOI: 10.1016/j.heliyon.2024.e27984. View

2.
Liu J, Shu Y, Zhu F, Feng B, Zhang Z, Liu L . Comparative efficacy and safety of combination therapy with high-dose sulbactam or colistin with additional antibacterial agents for multiple drug-resistant and extensively drug-resistant Acinetobacter baumannii infections: A systematic review and.... J Glob Antimicrob Resist. 2020; 24:136-147. DOI: 10.1016/j.jgar.2020.08.021. View

3.
Ocampo P, Lazar V, Papp B, Arnoldini M, Abel Zur Wiesch P, Busa-Fekete R . Antagonism between bacteriostatic and bactericidal antibiotics is prevalent. Antimicrob Agents Chemother. 2014; 58(8):4573-82. PMC: 4135978. DOI: 10.1128/AAC.02463-14. View

4.
Lawandi A, Yek C, Kadri S . IDSA guidance and ESCMID guidelines: complementary approaches toward a care standard for MDR Gram-negative infections. Clin Microbiol Infect. 2022; 28(4):465-469. DOI: 10.1016/j.cmi.2022.01.030. View

5.
Su M, Lyles J, Petit Iii R, Peterson J, Hargita M, Tang H . Genomic analysis of variability in Delta-toxin levels between strains. PeerJ. 2020; 8:e8717. PMC: 7100594. DOI: 10.7717/peerj.8717. View